HE3235, a synthetic adrenal hormone disease-modifying agent, in castrate resistant prostate cancer (CRPC): Results of phase I/II clinical trial Meeting Abstract
| Authors: | Montgomery, R. B.; Morris, M. J.; Ryan, C. J.; Stickney, D. R.; Frincke, J. M.; Reading, C. L.; Sarantopoulos, J.; Scher, H. I. |
| Abstract Title: | HE3235, a synthetic adrenal hormone disease-modifying agent, in castrate resistant prostate cancer (CRPC): Results of phase I/II clinical trial |
| Meeting Title: | 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 28 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2010 Jun 4-8 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2010-05-20 |
| Start Page: | 385s |
| Language: | English |
| ACCESSION: | WOS:000208852004043 |
| DOI: | 10.1200/jco.2010.28.15_suppl.4674 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 4674 -- S -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
